CYCN Cyclerion Therapeutics

Cyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference

Cyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference

CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing innovative medicines for people with serious diseases of the central nervous system (CNS), today announced that it will present a corporate overview at upcoming investor conferences:

  • 39th Annual J.P. Morgan Healthcare Conference. A presentation and Q&A discussion will take place on Thursday, January 14, 2021 at 3:40 p.m. ET and a live webcast may be accessed within the Investors & Media section of the  website. An archived replay will be available for approximately 90 days following the presentation.
  • H.C. Wainwright BioConnect Conference. An on-demand presentation will be available on Monday January 11, 2021 at 6:00 a.m. ET at the conference .

About Cyclerion Therapeutics 

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing innovative medicines for people with serious diseases of the central nervous system (CNS). Cyclerion’s lead program is CY6463 a pioneering CNS-penetrant sGC stimulator in clinical development for Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Alzheimer's Disease with Vascular pathology (ADv).

For more information about Cyclerion, please visit  and follow us on Twitter (@Cyclerion) and LinkedIn ().

Investors

Carlo Tanzi, Ph.D.

Kendall Investor Relations



EN
04/01/2021

Underlying

CYCNCyclerion Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cyclerion Therapeutics

 PRESS RELEASE
Free
CYCN Cyclerion Thera...

Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Comp...

Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth Cyclerion Has Renegotiated Praliciguat License Agreement to Obtain Upfront and Near-Term Payments as well as Entered into a License Option Agreement for Olinciguat CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company’s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strat...

December 17, 2024 1 EN
 PRESS RELEASE
Free
CYCN Cyclerion Thera...

Regina Graul, Ph.D., Promoted to Chief Executive Officer

Regina Graul, Ph.D., Promoted to Chief Executive Officer CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced that Regina Graul, Ph.D., has been promoted to Chief Executive Officer, President, and member of the Board of Directors. Since Dr. Graul joined Cyclerion as President in early December 2023, she has strengthened all aspects of the company. She has been working closely with the Board of Directors to prioritize building shareholder value by reducing Cyclerion’s operating costs while leading a world-class search and evaluati...

August 7, 2024 1 EN
 PRESS RELEASE
Free
CYCN Cyclerion Thera...

Cyclerion Appoints Regina Graul, Ph.D., as President

Cyclerion Appoints Regina Graul, Ph.D., as President – Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy – – Peter Hecht, Ph.D., will continue to work closely with Cyclerion leadership as a strategic consultant and longstanding board member; steps down from CEO role – CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a biopharmaceutical company on a mission to develop treatments for serious diseases, today announced that ...

December 4, 2023 1 EN
 PRESS RELEASE
Free
CYCN Cyclerion Thera...

Cyclerion Strengthens Board of Directors with Experienced Company Buil...

Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator - Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreaking wireless devices for passive assessment of symptoms, behavior, and treatment responses in neurological and psychiatric disorders - Michael Higgins: Seasoned biopharma executive possessing business and financial acumen with CEO and extensive board experience; former entrepreneur-in-residence at Polaris Partners with a track record of launching successful companies CAMBRIDGE, Mass., Nov. 30,...

November 30, 2023 1 EN
 PRESS RELEASE
Free
CYCN Cyclerion Thera...

Tisento Launches with $81 Million From Top-Tier Investor Syndicate and...

Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets         – Asset Purchase Agreement Closed; Cyclerion Received Equity Ownership in Tisento and Upfront Cash Payment – – Tisento Developing Zagociguat in MELAS*, a Rare Primary Mitochondrial Disease with No Approved Therapies, Leveraging Extensive Preclinical and Clinical Data Generated by Cyclerion – CAMBRIDGE, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Tisento Therapeutics, Inc. today announced the closing of the previously disclosed asset purch...

July 31, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch